Verona Pharma price target raised to $36 from $32 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma to $36 from $32 and keeps a Buy rating on the shares. The FDA approved the company’s lead candidate ensifentrine on schedule for the maintenance treatment of chronic obstructive pulmonary disease, the analyst tells investors in a research note.